BEIJING, Feb. 7 (Xinhua) – On Saturday, Sinovac Biotech Co., Ltd. (Sinovac Biotech) revealed that the China National Medicines Administration (NMPA) approved the sale. CoronaVac, the Company’s new coronavirus (COVID-19) vaccine, has been in the conditional market. On last Friday (Feb. 5)
Such vaccine It is produced by Sinovac Life Sciences Co., Ltd. (Sinovac Life Sciences) in Beijing. Capital of china Sinovac Biotech, a subsidiary of Sinovac, passed an emergency approval in China in June. It has been applied in emergencies to certain vulnerable populations in the country since last July.
Meanwhile, since January 2021, countries around the world such as Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos have continued to approve the domestic emergency use of Sinovac’s vaccine.
A statement on the Sinovac Biotech website states that the above countries accept vaccine clinical trials. It is believed that there is a clear feature in reducing medical treatment. Hospitalization Critically ill cases And deaths due to COVID-19 It is also of great importance to the prevention and control of pandemic.
Sinovac Life Sciences filed for the conditional release of the CoronaVac vaccine on the market on Feb 3, and it is approved. This is because the vaccine has been under two months of a Phase III clinical trial abroad.
The office requests that the company continue to conduct relevant clinical trials. Follow the terms and conditions And submit a follow-up to the research results within the deadline
“We hope to provide a safer and more effective vaccine as soon as possible. And help control COVID-19 From increasing vaccination rates To bolster social and economic development back to normalcy, ”said Yun Weitong, president and CEO of Sinovac Biotech.
The company stated that the vaccination process was divided into 2 doses, which were spaced 14-28 days, with each dose of 0.5 ml.
–
–
– .
